Clinical trial NCT00988780 - References

HIV Infections — Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Citation(s)

•   Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J
  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997 Jul 4;277(5322):112-6.
•   Battegay M, Nüesch R, Hirschel B, Kaufmann GR
  Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006 May;6(5):280-7. Review.
•   Bonnet MM, Pinoges LL, Varaine FF, Oberhauser BB, O'Brien DD, Kebede YY, Hewison CC, Zachariah RR, Ferradini LL
  Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS. 2006 Jun 12;20(9):1275-9.
•   Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Vicaut E, Lagrange PH, Sereni D, Autran B
  Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS. 2006 Jan 9;20(2):F1-7.
•   Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups
  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006 Mar 11;367(9513):817-24. Erratum in: Lancet. 2006 Jun 10;367(9526):1902.
•   Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC
  Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec;12(12):1365-71. Epub 2006 Nov 19.
•   Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, Sanchez J, Tabet SR
  Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):451-5.
•   Delves PJ, Roitt IM
  The immune system. First of two parts. N Engl J Med. 2000 Jul 6;343(1):37-49. Review.
•   Domingo P, Torres OH, Ris J, Vazquez G
  Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med. 2001 Jun 1;110(8):605-9.
•   Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M
  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997 Nov 8;315(7117):1194-9.
•   French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML
  Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000 Mar;1(2):107-15.
•   French MA, Price P, Stone SF
  Immune restoration disease after antiretroviral therapy. AIDS. 2004 Aug 20;18(12):1615-27. Review.
•   Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM
  Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One. 2008 Apr 2;3(4):e1915. doi: 10.1371/journal.pone.0001915.
•   Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT, Obel N
  Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS. 2004 Jan 2;18(1):89-97.
•   Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O
  The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005 Mar;6(2):140-3.
•   Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, Deeks SG, Douek DC, Brenchley JM
  Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15;199(8):1177-85. doi: 10.1086/597476. Erratum in: J Infect Dis. 2009 Jul 1;200(1):160.
•   Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, Kindelan JM, Carmona A, Juega J, Ocampo A; GEEMA Study Group
  Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002 Mar 8;16(4):605-13.
•   Lawn SD, Myer L, Bekker LG, Wood R
  CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006 Mar 21;6:59.
•   Lawn SD, Myer L, Bekker LG, Wood R
  Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007 Jan 30;21(3):335-41.
•   Lederman MM, Margolis L
  The lymph node in HIV pathogenesis. Semin Immunol. 2008 Jun;20(3):187-95. doi: 10.1016/j.smim.2008.06.001. Epub 2008 Jul 14. Review.
•   Lederman MM, Penn-Nicholson A, Cho M, Mosier D
  Biology of CCR5 and its role in HIV infection and treatment. JAMA. 2006 Aug 16;296(7):815-26. Review.
•   Lederman MM
  Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS. 2001 Feb;15 Suppl 2:S11-5. Review.
•   Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F; French Cryptococcosis Study Group
  Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005 Jul 1;19(10):1043-9.
•   Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A
  Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS. 2007 Jan 30;21(3):351-9.
•   Manabe YC, Campbell JD, Sydnor E, Moore RD
  Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):456-62.
•   Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S
  Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006 Dec;53(6):357-63. Epub 2006 Feb 17.
•   Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, Breux JP, Souala F, Allavena C, Raffi F, Garre M, Cartier F
  Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998 Oct 1;12(14):1815-22.
•   Murdoch DM, Venter WD, Van Rie A, Feldman C
  Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007 May 8;4:9.
•   O'Brien PC, Fleming TR
  A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56.
•   Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD
  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60.
•   Pandrea I, Apetrei C, Gordon S, Barbercheck J, Dufour J, Bohm R, Sumpter B, Roques P, Marx PA, Hirsch VM, Kaur A, Lackner AA, Veazey RS, Silvestri G
  Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood. 2007 Feb 1;109(3):1069-76. Epub 2006 Sep 26.
•   Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, Kim NJ, Oh MD, Choe KW
  Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. AIDS. 2007 Apr 23;21(7):875-7.
•   Ratnam I, Chiu C, Kandala NB, Easterbrook PJ
  Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006 Feb 1;42(3):418-27. Epub 2005 Dec 28.
•   Rodríguez-Rosado R, Soriano V, Dona C, González-Lahoz J
  Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antivir Ther. 1998;3(4):229-31.
•   Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, Prinz B, Youle M, Johnson MA
  Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004 Nov 5;18(16):2145-51.
•   Salkowitz JR, Sieg SF, Harding CV, Lederman MM
  In vitro human memory CD8 T cell expansion in response to cytomegalovirus requires CD4+ T cell help. J Infect Dis. 2004 Mar 15;189(6):971-83. Epub 2004 Mar 1.
•   Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, Hamill RJ
  Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005 Mar 4;19(4):399-406.
•   Sieg SF, Bazdar DA, Lederman MM
  S-phase entry leads to cell death in circulating T cells from HIV-infected persons. J Leukoc Biol. 2008 Jun;83(6):1382-7. doi: 10.1189/jlb.0907643. Epub 2008 Mar 27.
•   Sieg SF, Rodriguez B, Asaad R, Jiang W, Bazdar DA, Lederman MM
  Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. J Infect Dis. 2005 Jul 1;192(1):62-70. Epub 2005 May 26.
•   Singh N, Perfect JR
  Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007 Jun;7(6):395-401. Review.
•   Storey JD, Tibshirani R
  Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5. Epub 2003 Jul 25.
•   Westby M, van der Ryst E
  CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16(6):339-54. Review.
•   Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, Harries AD
  Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006 Nov 28;20(18):2355-60.

CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Details for clinical trial NCT00988780